Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI China ETF — how do they compare? Crispr Therapeutics AG trades at $53.87 (market cap $5.23B), while iShares MSCI China ETF trades at $55.1. Which is the better fit depends on your goals.
| CRSP | MCHI | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $66.99 |
52-Week Low | $44.34 | $50.48 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
MCHI, the iShares MSCI China ETF, trades at $55.2, down 3.04% over the past day. Technical indicators show a bullish overall signal with strong moving average support, while oscillators are neutral. The ETF is positioned near key support at $55. Recent news highlights China's strong export growth, particularly in AI and tech sectors, and institutional interest, though some funds have reduced holdings. A dividend of $0.36 per share is scheduled for payment in June 2026.
The outlook for MCHI is cautiously optimistic, driven by China's robust export performance and tech sector strength, but tempered by geopolitical tensions and regulatory risks. Investment opportunities include exposure to undervalued Chinese equities and AI-driven growth, while risks involve U.S.-China trade friction and potential economic slowdowns. Investors should weigh these factors against the ETF's current technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
